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Background: Mechanical ventilation is used to treat respiratory
failure in coronavirus disease 2019 (COVID-19).
Purpose: To review multiple streams of evidence regarding the
benefits and harms of ventilation techniques for coronavirus in-
fections, including that causing COVID-19.
Data Sources: 21 standard, World Health Organization–specific
and COVID-19–specific databases, without language restric-
tions, until 1 May 2020.
Study Selection: Studies of any design and language compar-
ing different oxygenation approaches in patients with coronavi-
rus infections, including severe acute respiratory syndrome
(SARS) or Middle East respiratory syndrome (MERS), or with hy-
poxemic respiratory failure. Animal, mechanistic, laboratory, and
preclinical evidence was gathered regarding aerosol dispersion
of coronavirus. Studies evaluating risk for virus transmission to
health care workers from aerosol-generating procedures (AGPs)
were included.
Data Extraction: Independent and duplicate screening, data
abstraction, and risk-of-bias assessment (GRADE for certainty of
evidence and AMSTAR 2 for included systematic reviews).
Data Synthesis: 123 studies were eligible (45 on COVID-19, 70
on SARS, 8 on MERS), but only 5 studies (1 on COVID-19, 3 on
SARS, 1 on MERS) adjusted for important confounders. A study
in hospitalized patients with COVID-19 reported slightly higher
mortality with noninvasive ventilation (NIV) than with invasive me-
chanical ventilation (IMV), but 2 opposing studies, 1 in patients
with MERS and 1 in patients with SARS, suggest a reduction in
mortality with NIV (very-low-certainty evidence). Two studies in
patients with SARS report a reduction in mortality with NIV com-
pared with no mechanical ventilation (low-certainty evidence).
Two systematic reviews suggest a large reduction in mortality
with NIV compared with conventional oxygen therapy. Other in-
cluded studies suggest increased odds of transmission from
AGPs.
Limitation: Direct studies in COVID-19 are limited and poorly
reported.
Conclusion: Indirect and low-certainty evidence suggests that
use of NIV, similar to IMV, probably reduces mortality but may
increase the risk for transmission of COVID-19 to health care
workers.
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As of 18 May 2020, the ongoing pandemic caused bysevere acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has affected more than 4.8 million individ-
uals worldwide and caused over 300 000 deaths (1).
SARS-CoV-2 spreads from person to person through
close contact and causes coronavirus disease 2019
(COVID-19); most deaths are caused by development of
hypoxemic respiratory failure and severe acute respira-
tory distress syndrome (ARDS).
Noninvasive ventilation (NIV), invasive mechanical
ventilation (IMV), and supportive therapies are the
mainstays of treatment of ARDS. Noninvasive ventila-
tion is associated with fewer adverse outcomes for pa-
tients than is IMV. However, NIV creates risks for the
health care workers (HCWs) caring for these patients,
because of SARS-CoV-2 transmission via aerosols (2).
The magnitude of this risk is not well explored in
COVID-19. In contrast, IMV typically uses a closed sys-
tem and thus carries a much lower risk for transmission
via aerosols. Countries with a large number of patients
with COVID-19 requiring mechanical ventilation have
experienced shortage of ventilators and have relied on
NIV, which includes continuous positive airway pres-
sure (CPAP), bilevel positive airway pressure (BiPAP),
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lines vary considerably in their recommendations on
the role and optimal method of NIV, reflecting differ-
ences in assumed effectiveness balanced with the risk
for infection to HCWs from aerosols.
Hypoxemic respiratory failure and ARDS are com-
mon in COVID-19, but the ideal way of providing ven-
tilation and the effect of NIV on HCWs is uncertain. Al-
though they are different from other causes of ARDS,
severe acute respiratory syndrome (caused by SARS-
CoV-1) or Middle East respiratory syndrome (caused by
MERS-CoV) may resemble ARDS in COVID-19 (3, 4).
Thus, evidence from SARS and MERS may be useful to
explore the effects of NIV.
Commissioned by the World Health Organization
(WHO) to inform their guidance documents, we ur-
gently but systematically reviewed evidence to assess
the benefits and harms of alternate noninvasive and in-
vasive ventilation strategies in acute hypoxemic respi-
ratory failure in patients with COVID-19. This included
searching for indirect evidence (for example, that re-
lated to SARS and MERS) and for evidence on the effect
of virus transmission on HCWs.
METHODS
By agreement with WHO on 3 April 2020, we per-
formed an urgent systematic review to compare the ef-
fect of different ventilation techniques on important pa-
tient outcomes and the risk for transmission for
coronavirus disease, including COVID-19. We adhered to
Cochrane systematic review methods, rated the certainty
of evidence by following the GRADE (Grading
of Recommendations Assessment, Development and
Evaluation) approach, prospectively registered the review
on PROSPERO (registration number CRD42020178187)
(Supplement 1, available at Annals.org), and followed
PRISMA (Preferred Reporting Items for Systematic reviews
and Meta-Analyses) reporting guidelines (5–9). We as-
sembled a large international collaborative team of re-
searchers, frontline and specialist clinicians, epidemiolo-
gists, patients, public health experts, and health policy
experts with expertise in systematic reviews. The review
addresses the following 4 streams of evidence: 1) studies
of any design that addressed NIV for individuals with
acute hypoxic respiratory failure caused by coronavirus
(COVID-19, MERS, SARS); 2) systematic reviews of ran-
domized trials that assessed the efficacy of NIV ap-
proaches in patients with hypoxemic respiratory failure
not due to coronavirus infection; 3) animal, mechanistic,
laboratory, and preclinical evidence regarding aerosol
dispersion of coronavirus; and 4) studies in adults evalu-
ating risk for virus transmission to HCWs from aerosol-
generating procedures (AGPs). When possible, results fo-
cus on information most relevant to SARS-CoV-2 and
COVID-19. Information related to the first stream of evi-
dence will be continually updated and maintained as a
living systematic review for at least 1 year.
Data Sources and Searches
Without language restrictions, we searched MEDLINE
(by using the OVID platform); PubMed; EMBASE; CI-
NAHL (by using the EBSCO platform); the Cochrane
Library; the COVID-19 Open Research Dataset, hosted
by Kaggle and created by the Allen Institute and col-
laborators; the COVID-19 Research Database main-
tained by the WHO; Epistemonikos (by using its
COVID-19 L·OVE [Living Overview of the Evidence]
platform); the EPPI Centre's living systematic map of
the evidence on COVID-19; ClinicalTrials.gov, the U.S.
National Library of Medicine's register of clinical trials;
and the WHO International Clinical Trials Registry Plat-
form (Supplement 2, available at Annals.org). We also
searched relevant documents on the websites of gov-
ernmental and other relevant organizations and refer-
ence lists of the included papers and relevant system-
atic reviews. We also hand-searched preprint servers
(bioRxiv, medRxiv, and preprints in The Lancet, part of
Social Science Research Network First Look). Finally, we
searched Chinese databases, including the WHO Chi-
nese database, the China Biomedical Literature Service
(SinoMed), the Chinese Scientific Journal Database
(VIP), the Wanfang database, and the China National
Knowledge Infrastructure (CNKI), until 1 May 2020
(Supplement 2).
The strategies combined Medical Subject Head-
ings and keywords related to COVID-19, NIV, and IMV,
as well as studies focusing on laboratory evidence re-
lated to virus spread via AGPs for the 4 streams de-
scribed above. We developed separate search strate-
gies for streams 1 (from 1 January 2002 to 1 May
2020), 2 (from 2017 to 1 May 2020), and 3 (inception
to 1 May 2020) with a senior information specialist.
We used the original search strategy (from inception
to 2010) for stream 4 from a review by the Canadian
Agency for Drugs and Technologies in Health
(CADTH) (restricted to the MEDLINE and EMBASE
databases and SARS-CoV-1, SARS-CoV-2, and MERS-
CoV until 1 May 2020) (2).
Study Selection
We included records addressing the following
population, interventions, comparisons, outcomes, and
study designs.
Population
We sought studies on patients with confirmed or
probable COVID-19 infection and hypoxemic respira-
tory failure. We planned to evaluate different sub-
groups (Supplement 1), including different age groups
and patients with comorbidities.
Interventions
Eligible interventions included NIV, including Bi-
PAP, CPAP, and HFNC; IMV via endotracheal tubes or
tracheostomy; standard oxygen therapy; or no me-
chanical ventilation. We determined a priori to evaluate
different types of interfaces (helmet, oronasal, or full-
face mask).
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Outcomes
Outcomes of interest were death, transmission of
COVID-19 to HCWs and other people, length of hospi-
tal and intensive care unit stay, complications of ther-
apy, secondary bacterial pneumonia, need for invasive
ventilation, need for tracheostomy, time to recovery from
COVID-19, aerosol generation and droplet dispersion of
live virus at various distances and times, and contextual
outcomes (acceptability, feasibility, resources use, effect
on equity).
Study Designs
Stream 1 consisted of studies of NIV in people with
any acute hypoxic respiratory failure caused by corona-
virus (COVID-19, MERS, or SARS). Evidence was priori-
tized by study design addressing the question of inter-
est as follows: 1) randomized controlled trials (RCTs); 2)
nonrandomized comparative studies; 3) noncompara-
tive studies (that is, case series); and 4) qualitative stud-
ies (for contextual outcomes). We excluded single case
reports.
Stream 2 consisted of systematic reviews published
in 2017 or later that synthesized randomized trial evi-
dence from patients with acute hypoxic respiratory fail-
ure who were critically ill but had neither suspected or
confirmed COVID-19, MERS, or SARS. We included
only recent credible systematic reviews (assessed by
using AMSTAR 2 [A Measurement Tool to Assess Sys-
tematic Reviews 2]) because we intended to focus on
up-to-date indirect evidence, and older reviews would
not have included the most recent studies. We summa-
rized the results of those reviews that are most credible
(moderate- or high-quality rating on AMSTAR 2).
In streams 3 and 4, to identify all evidence about
the risk for transmission of SARS-CoV-2 through AGPs,
we evaluated additional streams of evidence. In stream
3, we selected controlled studies (animal, human,
mechanistic, laboratory, preclinical, and simulation,
among others) evaluating aerosol dispersion to inform
the evidence about transmission of virus in confirmed
cases of COVID-19, MERS, or SARS. We focused on
COVID-19 in summarizing evidence, but if that evi-
dence was sparse, we decided a priori to summarize
evidence for MERS and SARS. For stream 4, we in-
cluded all primary studies dealing with SARS, MERS, or
COVID-19 published after 22 October 2010 (date of
prior search) (2). This update focused on transmission
of virus.
For all 4 streams, the reviewers pilot-tested a stan-
dardized title and abstract screening form by using the
same citations. We then conducted calibration exer-
cises by webinars for each stream. Once the form was
calibrated, pairs of reviewers screened in duplicate and
independently all titles and abstracts by using the eligi-
bility criteria. Conflicts between reviewers were re-
solved by consensus or by a senior methodologist
(H.J.S., D.C., E.A.A.). Reviewers pilot-tested a full-text
screening form and participated in a webinar using the
same 5 or more full-text articles. Once the form was
calibrated, the pairs of reviewers screened the full texts
independently and in duplicate and resolved any con-
flicts by discussion, or with the help of a senior meth-
odologist (H.J.S., D.C., E.A.A.). We recorded the pri-
mary reason for exclusion at the full-text screening
stage.
Data Extraction and Risk-of-Bias Assessment
For each of the 4 streams, we developed a stan-
dardized data abstraction form in Microsoft Excel and
piloted it as part of calibration exercises with all review-
ers. Teams of 2 reviewers extracted data in duplicate
and independently; all extracted data were verified by
2 biostatisticians (A.K. and R.B.) and a senior reviewer
(H.J.S., D.C., or E.A.A.). We extracted data on the fol-
lowing variables: study identifier; study design; setting;
population, intervention, and comparator characteris-
tics; outcomes (quantitative, if possible); source of
funding and reported conflicts of interest; ethical ap-
proval; and study limitations or other important com-
ments.
Two experienced reviewers performed the risk-of-
bias assessment, and a senior methodologist (H.J.S.
or E.A.A.) verified all assessments. We used the
Newcastle-Ottawa Scale for nonrandomized studies
(10, 11) and Cochrane Risk of Bias tool, version 2.0, for
randomized trials (12). We assessed systematic reviews
by using the AMSTAR 2 tool (13). We did not assess the
risk of bias for studies identified in stream 3.
Data Synthesis and Analysis
We synthesized the data in both narrative and tab-
ular formats. One reviewer (H.J.S.) graded the certainty
of the evidence by using the GRADE approach, and 2
senior reviewers (R.B. and E.A.A.) verified all assess-
ments. When applicable, we followed published guid-
ance for rating the certainty in evidence in the absence
of a single estimate of effect (14, 15). We used the
GRADEpro (www.gradepro.org) app to rate the evi-
dence and present it in GRADE evidence profiles and
summary of findings tables (16, 17) using standardized
terminology (18, 19).
For quantitative analyses, we only included com-
parative studies—those that allowed a comparison of at
least 2 interventions on an outcome of interest—in our
synthesis. Although we planned meta-analyses, most
studies provided unadjusted data or data that could
not be combined in a meta-analysis. We therefore did
not perform a meta-analysis and present raw numbers.
We present adjusted odds ratios (ORs) when studies
reported them, using RevMan (Cochrane).
Living Review and Literature Surveillance
We plan weekly literature surveillance through May
2021 for studies related to stream 1. This surveillance
and updating will focus on studies in patients with
COVID-19. We will use the search strategy for stream 1
(Supplement 1) and the selection, data abstraction, and
quality and certainty assessment methods described
above. We plan monthly updates or alerts that present
search findings and describe new evidence. If substan-
tive new literature emerges that changes our overall
conclusions, changes the certainty of evidence (20),
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provides data on additional outcomes, or provides data
that would be appropriate for meta-analysis with other
studies, we plan submission of an updated manuscript.
Role of the Funding Source
This systematic review was commissioned by the
WHO on 3 April 2020. The WHO helped define the
scope of the question but otherwise had no role in
study design, data collection, data analysis, data inter-
pretation, or writing of the report or the decision to
submit it for publication.
RESULTS
Stream 1: Systematic Review of Ventilation
Strategies in Patients With Hypoxemic
Respiratory Failure Due to Coronavirus
Infection
Among 38 942 records, 123 studies were eligible
(45 on COVID-19, 70 on SARS, 8 on MERS) in stream 1.
Supplement 3 (available at Annals.org) shows the
PRISMA flow diagram. Of these, 121 studies did not
provide adequate data for extraction—for example, be-
cause outcome data could not be attributed to a spe-
cific treatment group. Supplement 4 (available at An-
nals.org) shows a description of these studies. Of the
remaining 28 studies (11 on COVID-19, 15 on SARS, 2
on MERS) that had data for extraction (12, 21–47), 18
included NIV as a treatment of choice (Supplement 5,
available at Annals.org). Only 5 studies (including 1
very small RCT) provided results that we judged as ad-
equately adjusted for important confounders, such as
comorbidities or severity of hypoxemia (3 on SARS, 1
on COVID-19, and 1 on MERS) (12, 21, 29, 31, 32). We
considered the remaining 23 unadjusted studies as
providing results at high risk of bias. This included the
10 studies in patients with COVID-19 that reported un-
adjusted results.
We judged the risk of bias (Supplement 4 and Sup-
plement 5) as low for the cohort designs on the basis of
the Newcastle-Ottawa Scale, but in our GRADE assess-
ment, we accounted for the risks of selection and con-
founding bias due to the nonrandomized design, and
we noted some concerns for the RCT. We judged the
23 unadjusted studies, including all COVID-19 studies,
to be at moderate to high risk of bias because any es-
timate of effect will be subject to strong confounding
and selection bias. Furthermore, we identified studies
for which there was no clear comparison, mostly de-
fined as case series or case reports, which were gener-
ally at high risk of bias (Supplement 5).
Supplement 6 (available at Annals.org) shows the
results of the studies with extractable data. Five studies
reported adjusted results, one of them in patients with
COVID-19. In these latter studies, 3 studies compared
NIV with IMV and 2 studies compared NIV with no me-
chanical ventilation. The respective results from the for-
mer 3 studies (Figure 1) differ and suggest an impre-
cise increase in mortality in NIV compared with IMV in 1
study (COVID-19: hazard ratio, 1.61 [95% CI, 0.84 to
3.09]) and a reduction in mortality in 2 studies (MERS
and SARS: OR, 0.61 [CI, 0.23 to 1.6] and 0.24 [CI, 0.10
to 0.72], respectively) (very low certainty of the evi-
dence secondary to the nonrandomized study designs
and concerns about inconsistency) (21, 29, 31). We
were unable to perform a meta-analysis because of dif-
ferences in how authors reported the effect estimates.
For NIV compared with no mechanical ventilation, the
RCT (32) suggested a reduction in mortality, but there
were only 3 events in 60 patients in total, causing im-
precision, and the nonrandomized study by Xu and col-
leagues (12) also showed a reduction in mortality (OR,
0.21 [CI, 0.09 to 0.47]; low certainty, owing to very se-
rious imprecision of the RCT and the nonrandomized
study design of the other study) (Figure 2).
The 10 additional studies in COVID-19 presented
only unadjusted results. In the only study from Italy,
Duca and associates (25) reported a higher death rate
in patients receiving helmet CPAP or other NIV com-
pared with IMV. For the 3 studies from China, Liao and
coworkers (28) reported rates of recovery greater than
40% after 28 days of follow-up in patients who received
NIV, HFNC, and conventional oxygen therapy. Wang
and colleagues (29) found low rates of the need for
IMV in patients receiving NIV or HFNC. Mortality was
greater than 60% in the NIV group and was 100% in the
IMV group in the study by Wu and associates (30). We
did not calculate effect estimates for these latter stud-
ies, given the high risk for confounding and selection
bias as well as other potential biases in these studies.
We found only 1 study on contextual factors, which re-
Figure 1. Mortality with NIV versus IMV.
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Three studies (21, 29, 31) comparing NIV with IMV suggested both an increase and a reduction in mortality. COVID-19 = coronavirus disease 2019;
IMV = invasive mechanical ventilation; IV = inverse variance; MERS = Middle East respiratory syndrome; NIV = noninvasive ventilation; SARS =
severe acute respiratory syndrome.
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ported a 2.5-fold higher cost for patients with SARS
treated with mechanical versus no mechanical ventila-
tion from 2004. We found no studies that provided in-
formation on any of the contextual factors for decision
making about NIV in COVID-19.
Stream 2: Overview of Systematic Reviews of
Randomized Trials That Assessed the Efficacy of
NIV Approaches in Patients With Hypoxemic
Respiratory Failure Not Due to Coronavirus
Infection
We identified 12 systematic reviews of indirect
study populations that were judged to be credible on
the basis of assessment with the AMSTAR 2 instrument
(rating of moderate or high quality). Supplement 7
(available at Annals.org) provides the full ratings, and
Supplement 3 shows the PRISMA flow chart. Consulta-
tion with our 7 content experts who are involved in care
of patients with hypoxemic respiratory failure, including
those with COVID-19, identified no additional system-
atic review that would have superseded the identified
reviews, but 5 of these reviews included study popula-
tions that we judged as too indirect on final review (48–
52)—for example, because they were studies in postsur-
gery patients or those with cardiogenic pulmonary
edema only (Supplement 7). We found no systematic
review comparing IMV with NIV. We found no studies
allowing us to draw conclusions about the indirect
comparative efficacy of CPAP or BiPAP in COVID-19.
Two systematic reviews (53, 54) concluded that
RCTs suggest a large reduction in mortality of NIV com-
pared with conventional oxygen therapy for acute hy-
poxemic respiratory failure (Supplement 7). We in-
cluded 4 systematic reviews of RCTs that compared
HFNC, which is considered an NIV strategy by many
content experts, with conventional oxygen therapy for
adults (55–58) and 1 in children (59). The results overall
suggested no reduction in mortality but a reduction in
the need for IMV with the administration of HFNC.
Compared with other NIV, 2 of the reviews of RCTs in
adults (56, 57) suggested that HFNC had no effect on
mortality or escalation of ventilatory support, including
the need for intubation. The RCTs included in 1 review
suggested that helmets are at least as efficacious as the
use of facemasks in NIV (53). In children, the risk for
treatment failure and mortality appeared to be in-
creased with HFNC compared with CPAP (59) (Supple-
ment 7).
Stream 3: Systematic Review of Mechanistic,
Animal, Human, Foundational Science,
Preclinical, and Other Studies Describing the
Risk for Transmission From AGPs
To determine the risk for transmission of COVID-
19, we conducted a systematic review of mechanistic,
animal, human, preclinical, laboratory, and other stud-
ies and identified 25 102 citations; Supplement 3
shows the PRISMA flow chart for the included studies.
We included 6 studies assessing the presence or trans-
mission of the 3 coronaviruses in different environ-
ments: MERS-CoV (2 studies) (60, 61), SARS-CoV (1
study) (62), and SARS-CoV-2/COVID-19 (3 studies) (63–
65). Wan and colleagues (62) studied droplet distribu-
tion of SARS-CoV when patients with SARS used a hu-
midifier or a large-volume nebulizer and found that
none of the air samples had SARS-CoV–specific DNA
products. One study found that SARS-CoV-2 persisted
up to 16 hours in airborne form (64), and another re-
ported a higher rate of SARS-CoV-2 detection in the
intensive care setting where patients were ventilated
(67% of air outlet swab samples and 44% of swab sur-
face samples) (65). Adhikari and coworkers (60) mod-
eled the transmission of MERS-CoV to HCWs visiting an
index patient, other patients sharing the same room,
and family visitors. The risk was highest among HCWs
and mostly depended on the concentration of MERS-
CoV in the saliva. Pyankov and associates (61) used a
virus-containing suspension aerosolized to an experi-
mental aerosol chamber to compare, under controlled
laboratory conditions, particle size and viable concen-
tration of MERS-CoV in 2 different environments. They
found higher evaporation and lower survival under hot
and dry climatic conditions. Similarly, Bae and col-
leagues (63) found that coughing induces dissemina-
tion of SARS-CoV-2 and masks did not prevent coloni-
zation at a distance of 20 cm.
Stream 4: Update of Systematic Reviews of
Human Studies Evaluating the Effect of AGPs
In 2011, CADTH produced a rapid response report
that systematically reviewed the risk for transmission of
acute respiratory infection to HCWs exposed to pa-
Figure 2. Mortality with NIV compared with no MV.
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Liu, 2004 (32): SARS, RCT
Xu et al, 2010 (12): MERS, NRS, adjusted
0.13 (0.01–2.10)
0.21 (0.09–0.47)
One RCT (32) suggests a reduction in mortality, but there were only 3 events in 60 patients in total, causing imprecision. The nonrandomized study
by Xu and colleagues (12) showed a reduction in mortality. IV = inverse variance; MERS = Middle East respiratory syndrome; MV = mechanical
ventilation; NIV = noninvasive ventilation; NRS = nonrandomized study; RCT = randomized controlled trial; SARS = severe acute respiratory
syndrome.
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tients undergoing AGPs (2). The review included 5
case–control studies and 5 cohort studies evaluating
the risk for SARS transmission to HCWs during AGPs
(Supplements 8, 9, and 10, available at Annals.org).
Only 4 of these studies provided adjusted effect esti-
mates. The studies found large increases in the odds of
SARS-CoV infection among HCWs performing or being
present during tracheal intubation, or in HCWs per-
forming chest compressions (66–69). Unadjusted stud-
ies reported an increased risk for transmission with tra-
cheal intubation, NIV, manipulation of a BiPAP mask,
and manual ventilation before intubation. Other AGPs
were not associated with transmission in that report:
endotracheal aspiration, suction of body fluids, bron-
choscopy, nebulizer treatment, administration of oxy-
gen, high-flow oxygen, defibrillation, insertion of naso-
gastric tube, and collection of sputum (Supplement 11,
available at Annals.org).
Our update of this review identified 15 new studies
(6 on COVID-19 and 9 on MERS), but these studies had
high risk of bias (Supplement 12 and 13, available at
Annals.org; Supplement 3 shows the PRISMA flow dia-
gram). Most studies used real-time polymerase chain
reaction to ascertain presence of virus. Three studies
found no cases of transmission to HCWs in the follow-
ing AGPs: bronchoscope-guided endotracheal intubation
through nasal insertion (70); tracheostomy (71); endotra-
cheal intubation, extubation, or NIV; and exposure to
aerosols in an open circuit (72). Two additional studies
reported no important association between the propor-
tions of HCWs contracting acute respiratory illness in
high-risk exposure versus other exposure in COVID-19
(73, 74), but another found that being present during
or assisting with AGPs (nebulizer treatment or BiPAP)
was more common among HCWs with COVID-19 (75).
One study found an 11% infection rate among anesthe-
tists who had direct contact with patients with
COVID-19 who received oxygen via nasal cannula (76).
Hall and colleagues (77) reported no infection among
HCWs reporting contact with patients with MERS-CoV,
although a proportion of them had been present dur-
ing AGPs (airway suction, nebulizer treatment, sputum
induction, bronchoscopy, and intubation). Alraddadi
and associates (78) reported different rates of infection
among HCWs in direct contact with patients and
among those performing AGPs, and 2 case reports (79,
80) described infection with MERS-CoV after being
present at cardiac resuscitations and having face-to-
face contact with a febrile HCW. However, these find-
ings need to be interpreted with great caution, owing
to a probable confounding effect of personal protec-
tive equipment (PPE) use and variable methods and re-
porting (81–84).
DISCUSSION
This systematic review evaluating different ventila-
tion strategies identified 28 original comparative stud-
ies in patients with SARS, MERS, and COVID-19. Al-
though an additional 34 studies in patients with
COVID-19 were found, their methods and reporting
were too poor for us to synthesize data appropriately.
Together, the indirect evidence, including 7 systematic
reviews in other populations, suggests that NIV may re-
duce mortality or need for IMV, with similar effects to
IMV. However, the use of NIV and the choice of the
ventilation strategy must be balanced against the po-
tentially increased risk for infection of HCWs resulting
from these AGPs. One study in patients with COVID-19
that used CPAP with helmets, and RCTs included in 1
systematic review, suggested that helmets are at least
as efficacious as masks in NIV (25, 54, 85), and they
have been used in children (86). Very limited evidence
suggests that helmets may reduce the risk for transmis-
sion. Two additional comprehensive searches identi-
fied evidence that suggests a risk for infection for
HCWs with COVID-19, SARS, and MERS (2). Tables 1
and 2 provide GRADE evidence profiles for 2 key com-
parisons (NIV versus IMV and NIV versus no mechanical
ventilation), synthesizing the evidence and rating the
certainty across the different streams for the most direct
evidence (COVID-19, SARS, and MERS). Overall, the
certainty of evidence is very low to low based on the
observational design, which raises concerns about risk
of bias. We did not rate down the evidence from pa-
tients with SARS or MERS for indirectness, because
these diseases are caused by viruses belonging to the
same family and subtype as SARS-CoV-2.
We are not aware of systematic reviews on the best
NIV strategies in patients with COVID-19 who have
acute hypoxemic respiratory failure. The adherence to
full systematic review methods, inclusion of all lan-
guages, use of the GRADE approach (7), consideration
of indirect evidence, and use of different streams of
evidence are strengths of our urgent review. We also
retrieved a total of 660 guidelines, of which 9 focused
on COVID-19 (Table 3) (88–96). Of note, HFNC is not
recommended by NHS England, although it is recom-
mended by the other guideline bodies. Besides the
Australian and New Zealand Guideline bodies and the
American Association for Respiratory Care, most guide-
line bodies recommend CPAP conditionally in selected
patients.
Our study has limitations. The included original
studies had poor reporting quality and were mostly ob-
servational, with inappropriate control for confounding
or selection bias or with only single arms. The sole ad-
justed study of NIV in patients with COVID-19 was im-
precise and included an inappropriately large number
of variables in the regression model to produce reliable
results. Furthermore, studies had mixed approaches to
using NIV. In some, IMV was unavailable, and in others,
IMV was used when NIV failed, which can introduce
severe selection bias. Although we identified many
studies in COVID-19, the most robust studies were in
patients with MERS or SARS.
In stream 3, the 6 identified mechanistic and labo-
ratory studies of the risk for transmission from AGPs did
not allow quantitative risk estimates. In stream 4, we
noted, similarly to the CADTH review (2), a risk of bias
related to confounding due to use of PPE, which inves-
tigators often did not adjust for (74, 79, 97, 98).
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Although our data are largely observational (with
the exception of 1 small RCT in patients with SARS) and
the degree of indirectness still needs to be determined
on the basis of new evidence emerging about the sim-
ilarities of SARS, MERS, and COVID-19, prior systematic
reviews could not evaluate the effect of NIV on impor-
tant outcomes in patients infected with coronaviruses.
At a minimum, our review serves as a snapshot of the
best available evidence. Clinicians should consider us-
ing NIV only when appropriate PPE is available to pro-
tect HCWs from the infection.
It is important that researchers performing obser-
vational studies adhere to reporting standards, even
during pandemics. What is needed to protect HCWs
and prepare for the next pandemic are robust, well-
reported studies on strategies to improve the out-
comes of patients and protect those who care for them.
Although pharmacotherapeutics and vaccines are in
the limelight, simple process-of-care measures and
common support strategies must be systematically
documented and analyzed to adequately prepare for
the future. Better studies are needed to inform practice
guidelines and reduce inconsistency among their rec-
ommendations (ongoing studies are listed in Supple-
ment 14, available at Annals.org).
In conclusion, our systematic review examined dif-
ferent streams of evidence, including original human
studies evaluating different modalities of NIV, IMV, and
HFNC in COVID-19, SARS, and MERS; systematic re-
views in other populations; mechanistic and laboratory
evidence; and studies of AGPs. We found low-certainty
evidence that NIV may have similar effects as IMV but
reduce mortality compared with no IMV in patients with
COVID-19 (stream 1). Evidence in other populations
with acute hypoxic respiratory failure suggests that NIV
improves outcomes compared with conventional oxy-
gen therapy and HFNC (stream 2). However, that evi-
dence is indirect and very limited in children. We
searched for but did not identify well-done mechanistic
and other laboratory studies that allow quantification of
virus transmission risk (stream 3). However, evidence in
stream 4 suggests an increased risk for transmission of
coronaviruses with invasive procedures, such as intuba-
tion and NIV, but also that risk for transmission was dif-
ficult to quantify exactly. On the basis of this and other
reviews, PPE may reduce for some the risk for transmis-
sion during AGPs, but it will not abolish it. The poor
quality of conduct and reporting of studies on the ef-
fects of NIV on important outcomes in COVID-19 is
striking.
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